Endoluten

Endoluten is a Khavinson-class peptide bioregulator derived from pineal gland tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore physiological circadian regulation and melatonin synthesis by modulating gene expression in aging pineal epithelial cells through interaction with chromatin regulatory elements. As a pineal tissue-derived bioregulator, Endoluten operates within the mechanistic framework established for the Khavinson class: short peptides (2–4 amino acids) are proposed to bind specific DNA regulatory sequences in tissue-target cells, activating gene expression programs that decline with age and restoring physiological function through epigenetic mechanisms rather than receptor agonism. Published research on Khavinson-class peptide bioregulators as a class has characterized this peptide-DNA interaction mechanism and documented restorative effects on tissue-specific physiological parameters in aging animal models and human observational studies, providing class-level biological plausibility for pineal peptide bioregulators as age-related circadian and neuroendocrine regulators. Endoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed published studies using the Endoluten name specifically characterize its clinical outcomes in controlled trials, and its use is confined to the Russian integrative and anti-aging medicine context where Khavinson bioregulators are commercially available.